Upload
others
View
15
Download
0
Embed Size (px)
Citation preview
GLOBAL HEALTH ECONOMICS AND OUTCOMES RESEARCHFELLOWSHIP PROGRAMUNIV OF WASHINGTON2019-2021
AGN7980_Allergan UW Fellowship Brochure_2018-mech.indd 1 10/15/18 10:26 AM
GHEOR Fellowship Program 2019-2021GHEOR Fellowship Program 2019-2021GHEOR Fellowship Program 2019-2021GHEOR Fellowship Program 2019-2021GHEOR Fellowship Program 2019-2021GHEOR Fellowship Program 2019-2021
PRODUCT VALUE PROPOSITION…outcomes research strategy based on product value, stakeholder needs & insights
VALUE COMMUNICATION …about evidence informing the value proposition to stakeholders
…informs health care decision making
EVIDENCE GENERATION AND TOOL DEVELOPMENT…through clinical and health economics & outcomes research (HEOR) data
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in
a new industry model – Growth Pharma. We are focused on developing, manufacturing and commercializing branded
pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.
We market a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical
aesthetics and dermatology, gastroenterology, women’s health, urology and anti-infective therapeutic categories.
We are an industry leader in Open Science, a model of research and development, which defi nes our approach to
identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan
has built one of the broadest development pipelines in the pharmaceutical industry with 65+ mid-to-late stage pipeline
programs currently in development. Learn more at www.Allergan.com.
ABOUT OUR COMPANY
OUR WORLD-CLASS MANUFACTURING AND R&D NETWORK
GLOBAL HEALTH ECONOMICS AND OUTCOMES RESEARCH (GHEOR)
1
2
3
1 GHEOR Fellowship Program 2019-2021
USABranchburg, NJ Cincinnati, OHNorthern CA (Biologics)Irvine, CA (Biologics)Dublin, CAWaco, TXHouston, TXBridgewater, NJIrvine, CAPleasanton, CASunrise, FLMadison, NJ
COSTA RICASan Jose
BRAZILGuarulhosSão Paulo
IRELANDClonshaughGalwayWestport
BELGIUMLiege
GERMANYWeiterstadt
FRANCEPringyPringy
MANUFACTURING CANADAMarkham
CHINABeijingShanghai
JAPANTokyo
UKLiverpoolMarlow
R&D
SINGAPORESingapore
AGN7980_Allergan UW Fellowship Brochure_2018-mech.indd 2 10/15/18 10:26 AM
The University of Washington is a world-class leader in health sciences education and has been consistently listed in
US News and World Report as one of the top 10 institutions for its graduate programs. The University is particularly
noted for its strong research programs and since 1974 has received more federal funds for research and training
than any other public university in the United States. It fosters a highly collegial atmosphere between departments
and academic units, creating a particularly attractive environment for such partnerships between the public and
private sectors.
The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute is housed within the University of
Washington School of Pharmacy, which boasts nearly 125 years of academic and research success. Faculty in the
program (1) provide advanced research training for graduate students, post-doctoral fellows and clinicians (PharmDs,
MDs); (2) conduct rigorous scientific research in economic evaluations and outcomes of pharmaceuticals and other
health technologies, and (3) translate and disseminate the results of research into clinical practice and healthcare
policy, with the goal of improving patient care.
The CHOICE Institute faculty participating in the fellowship have been chosen both for their dedication to teaching and
their excellence in research. Each is trained either as a health economist or health services researcher and all have an
extensive history of eff ective economic evaluations and pharmacoepidemiologic research.
ABOUT OUR SCHOOL
GHEOR Fellowship Program 2019-2021 2
AGN7980_Allergan UW Fellowship Brochure_2018-mech.indd 3 10/15/18 10:26 AM
GHEOR Fellowship Program 2019-2021
UNIVERSITY OF WASHINGTON
Beth Devine, PharmD, MBA, PhD, FASHP
Professor, Director of Graduate Programs
The Comparative Health Outcomes, Policy,
and Economics (CHOICE) Institute
1959 NE Pacifi c St, H-375D
Box 357630
Seattle, WA 98195-7630
E-Mail: [email protected]
THE FELLOWSHIP PROGRAM Allergan and the University of Washington are pleased to off er two, 2-year GHEOR Fellowship positions for the academic
year 2019-2021. Fellows will spend their fi rst year at the University of Washington (Seattle, WA), and the second year at
Allergan (Irvine, CA). The objective of the fi rst year is to educate fellows on the principles and methods used in health
economics and outcomes research. During the second year, fellows are provided with opportunities to gain practical
knowledge and experience with the use of clinical, economic, and humanistic data by supporting the development and
commercialization of pharmaceutical products. This will be accomplished by participating in work activities undertaken
by the GHEOR team.
Compensation includes a competitive stipend, basic medical insurance, conference attendance, relocation from
Seattle to Irvine, and holiday/vacation time. A Master’s (MS) Degree is awarded upon completion of all course
requirements and thesis project.
ALLERGAN PLC
Patrick Gillard, PharmD, MS
Executive Director, General Medicine,
Global Value and Evidence
2525 Dupont Drive
Irvine, CA 92612
E-Mail: [email protected]
Phone: (714) 246-2354
FELLOWSHIP DIRECTORS
The Allergan/University of Washington GHEOR Fellowship is a two-year program that provides training and hands-on experience in a broad-range of health economics and outcomes research topics. The program is structured to allow fellows to gain profi ciency in health outcomes strategy and research as conducted
in both academic and pharmaceutical industry settings.
3
ABOUT OUR FELLOWSHIP
AGN7980_Allergan UW Fellowship Brochure_2018-mech.indd 4 10/15/18 10:26 AM
GHEOR Fellowship Program 2019-2021
FIRST YEAR OBJECTIVESThe objective of the fi rst year is to provide the fellow with the research tools necessary for economic evaluation and
policy assessment. The fellow will be given an overview of pharmaceutical economics and general health policy,
and taught methods of economic assessment, health services research, epidemiology, clinical research design, and
biostatistical analyses.
The fellow will be assigned a MS thesis project which is selected based on input from both Allergan as well as the
University of Washington mentors. Fellows are highly encouraged to complete their MS project during their fi rst year.
Additionally, fellows will also engage in ongoing projects with Allergan throughout their fi rst year, applying skills from
previous pharmacy training as well as integrating new techniques developed from University of Washington courses.
Applying learning to solve real-world problems is a constant focus of the fellowship.
The fellow’s actual course of study will be developed on an individual basis with the Program Director, Dr. Beth Devine,
but will consist of courses in biostatistics, epidemiology, economic evaluations and outcomes research, and health
and pharmaceutical policy.
AFTER COMPLETION OF THE FIRST-YEAR, THE FELLOW WILL HAVE A CLEAR UNDERSTANDING OF:• General principles of economics and in particular how economics infl uences the use, cost, and availability
of pharmaceuticals.
• The complex structure of drug policy and how it determines relationships between consumers, health care providers,
insurers, payers, and government agencies.
• The breadth and scope of analytical methods needed for the assessment of Patient Reported Outcomes (PROs),
economic modeling, retrospective database studies, and observational studies.
• Formulary development, maintenance and evaluation in institutional, managed care, and state-level
government programs.
1ST YEAR
FELLOWSHIP STRUCTURE
4
AGN7980_Allergan UW Fellowship Brochure_2018-mech.indd 5 10/15/18 10:26 AM
GHEOR Fellowship Program 2019-2021
SECOND YEAR OBJECTIVESThe second year of training will be at Allergan in Irvine, CA with the GHEOR department. This part of the program
is designed to allow the fellow to learn about the role of economic evaluations and outcomes research in the drug
development and commercialization process within the industry setting. The research may be on an existing or
experimental product, for a disease state that is of interest to Allergan.
In addition to completing individual research project(s), fellows will participate in ongoing economic evaluations,
outcomes research, and other projects in collaboration with the GHEOR team. These experiences will provide
the fellow with opportunities to interact with team members in other
departments at Allergan to learn how economic analyses and outcomes
research are used throughout the pharmaceutical industry. Fellows will
see fi rsthand how outcomes research is utilized to demonstrate the
place of Allergan products in treatment pathways and its value.
2ND YEAR
5
AGN7980_Allergan UW Fellowship Brochure_2018-mech.indd 6 10/15/18 10:26 AM
GHEOR Fellowship Program 2019-2021
Jonathan W. Kowalski, PharmD, MS
Vice President, US HOV
Sepideh Varon, PhDAssociate Vice President, GHEOR
David Macarios, MBA, MSc
Vice President, GEV
Hema Viswanathan, BPharm, PhD
Executive Director, GHEOR
Amy Tung, PharmD, MS
Senior Manager, GHEOR
Patrick Gillard, PharmD, MS
Executive Director, GHEOR
Joanna Campbell, PhDExecutive Director, GHEOR
ALLERGAN FELLOWSHIP MENTORS
Vaishali Patel, PharmD, MS
Executive Director, GHEOR
UNIVERSITY OF WASHINGTON PROGRAM FACULTY• Anirban Basu, PhD Professor and Stergachis Family Endowed
Director of The CHOICE Institute
• Denise Boudreau, PhD Affi liate Professor
• Beth Devine, PharmD, MBA, PhD, FASHP
Professor, Director of Graduate Programs
• Josh Carlson, MPH, PhD Associate Professor
• Louis P. Garrison, Jr., PhD Professor Emeritus
• Ryan Hansen, PhD, PharmD Assistant Professor
• Thomas K. Hazlet, PharmD, Dr. PH Associate Professor
• Scott D. Ramsey, MD, PhD Professor
• Sean D. Sullivan, PhD Professor and Dean of
School of Pharmacy
• David L. Veenstra, PharmD, PhD Professor and Associate Director of
The CHOICE Institute
• Joseph Babigumira, MBChB, MS, PhD
Adjunct Associate Professor
• Aasthaa Bansal, PhD Assistant Professor
• Andy Stergachis, BPharm, PhD Professor and Associate Dean for Research,
Graduate Programs and New Initiatives
• Douglas Barthold, PhD Research Assistant Professor
• Shelly Gray, PharmD, MS Professor
• Zachary Marcum, PharmD, MS, PhD
Assistant Professor
6
Anand Shewale, MS, PhD
Senior Manager, GHEOR
Sarah Baradaran, PharmD, MS
Senior Manager, GHEOR
Kate Burslem, MScExecutive Director, GHEOR
Mousam Parekh, MSManager, GHEOR
AGN7980_Allergan UW Fellowship Brochure_2018-mech.indd 7 10/15/18 10:27 AM
GHEOR Fellowship Program 2019-2021
JAMIE TA, PHARMDJamie received her PharmD from the University of California, San Diego Skaggs School of Pharmacy and
Pharmaceutical Sciences in 2018. Prior to the fellowship, Jamie gained experiences in HEOR, managed care,
corporate development, and market access in the pharmaceutical industry, PBM, health plan, and consulting
settings. Throughout pharmacy school, Jamie worked at MedImpact Healthcare Systems, Inc., where
she worked on outcomes research, specialty pharmacy, and analytics projects to support clinical product
development. Jamie also served as the AMCP/Pfi zer, Inc. Managed Care Pharmacy Intern at SelectHealth,
where she conducted a retrospective claims database analysis to evaluate real-world adherence and clinical
outcomes of new diabetes medications in a managed care plan population. Jamie completed a rotation in
the Global Health Economics and Outcomes Research department at Allergan, where she was involved
in systematic literature review and claims database studies to support a Phase 3 product. At UCSD, Jamie
served as President of the AMCP-UCSD student chapter and was a member of UCSD’s winning national P&T
Competition team.
Jamie is excited to work with the UW CHOICE faculty and Allergan team to further develop her skills in HEOR.
For her thesis, she will be using MarketScan data to determine adherence, healthcare resource utilization, and
costs among patients treated with antidepressants.
ASHLEY KIM, PHARMDAshley is a graduate from the University of California, San Francisco (UCSF) School of Pharmacy. Prior to joining
the fellowship, she was a Health Economics & Outcomes Research intern at Genentech, where she analyzed
the epidemiology of multiple cancer types using the SEER database for budget impact analyses, assessed
patient-reported outcome data, and informed research strategy around assessing the cost of adverse events in
oncology. During her time at UCSF, she further conducted a systematic literature review surrounding the virtual
healthcare landscape and completed a clerkship in Pricing, Reimbursement, and Market Access at Eli Lilly,
where she analyzed the impact of value-based frameworks on an existing oncology drug to evaluate internal
value and access assumptions and forecasting.
Ashley is very excited to join the CHOICE institute and learn from exceptional faculty and hone her skills in
economic modeling, real world evidence generation, and outcome analyses. For her thesis, she will be using
Truven MarketScan data to characterize the disease burden and progression of geographic atrophy.
1ST YEAR FELLOWS
CURRENT FELLOWS
7
AGN7980_Allergan UW Fellowship Brochure_2018-mech.indd 8 10/15/18 10:27 AM
GHEOR Fellowship Program 2019-2021
SARA HIGA, PHARMD, MSSara received her PharmD from the University of Maryland Baltimore and her BS and MS degrees from
Georgetown University. For the fi rst year of the fellowship, Sara worked under the mentorship of Drs. Aasthaa
Bansal, Beth Devine, Vaishali Patel, and Sarah Baradaran. At the University of Washington, she conducted a
retrospective claims analysis to describe psoriasis treatment patterns for her master’s thesis.
Currently, she is working with Vaishali Patel, Mousam Parekh, and Julie Garcia to support breast reconstruction
and Botox projects. Sara is excited to continue her training and apply her skills in real-world evidence, patient-
reported outcomes research, and economic evaluation.
ABSTRACTS FROM FELLOWSHIP: 1. Higa S, Rueda JD, Devine B. Cost-Utility Analysis of Initial Treatment with Apremilast versus Methotrexate
in Systemic-Naïve Patients with Plaque Psoriasis. ISPOR 23rd Annual International Meeting, May 2018,
Baltimore, MD. (Poster)
2. N’Dri L, Higa S. A Cost-Utility Analysis of Atovaquone-Proguanil vs. Artemether-Lumefantrine for the
Treatment of Uncomplicated Malaria in the U.S. ISPOR 23rd Annual International Meeting, May 2018,
Baltimore, MD. (Poster)
3. Higa S, Devine B. Psoriasis Treatment Patterns: A Systematic Review. UW Corporate Advisory Board Meeting,
September 2017, Seattle, WA. (Poster)
MANUSCRIPTS FROM FELLOWSHIP:
1. Higa S, Devine B, Patel V, Baradaran S, Wang D, Bansal A. Psoriasis Treatment Patterns: A Retrospective
Claims Study. (In Progress)
CHIEMEKA IKE, MPH, PHARMD, MSChiemeka received her PharmD from the University of Houston and her MPH in Epidemiology and Biostatistics
from the George Washington University. For the fi rst year of the fellowship, Chiemeka worked under the
mentorship of Drs. Beth Devine, Zachary Marcum, Hema Viswanathan, and Anand Shewale. For her master’s
thesis, she analyzed a cross-sectional survey using Adelphi Real-World® data to describe treatment patterns
for acute medications of migraine.
Currently, she is working with Anand Shewale and Hema Viswanathan to support various migraine projects.
Chiemeka is excited to continue her training and continue to hone her skills in real-world evidence, patient-
reported outcomes research, and health economic evaluation.
ABSTRACTS FROM FELLOWSHIP:1. Ike C, Devine B. Cost-Utility Analysis of Oral Sumatriptan Versus Oral Ergotamine/Caff eine in the Treatment
of Acute Migraine Attacks. ISPOR 23rd Annual International Meeting, May 2018, Baltimore, MD. (Poster)
2. Ike C, Devine B. Treatment, Switching, and Cycling Patterns of Acute Medications for Migraine: A Systematic
Review. UW Corporate Advisory Board Meeting, September 2017, Seattle, WA. (Poster)
MANUSCRIPTS FROM FELLOWSHIP:1. Ike C, Marcum Z, Shewale A, Viswanathan H, Cotton S, Johnson C, Jackson J, Devine B. Treatment Patterns,
Discontinuation and Switching of Acute Medications for Migraine: A Cross-Sectional Survey of Real-World
Evidence from a Multi-Country Perspective. (In Progress)
2ND YEAR FELLOWS
8
AGN7980_Allergan UW Fellowship Brochure_2018-mech.indd 9 10/15/18 10:27 AM
GHEOR Fellowship Program 2019-2021
Senior Manager, Global Health Economics and Outcomes Research
Allergan plc, Irvine, CA
MANUSCRIPTS FROM FELLOWSHIP1. Shih V, Campbell J, Devine EB. The Association between Onset of Vision Impairment and Functional Limitations and Informal Caregiving
Requirements in Older Americans. (In Progress)
Pharmacy Quality, Utilization, and Clinical Programs Coordinator Kaiser Permanente of Washington
Seattle, WA
MANUSCRIPTS FROM FELLOWSHIP 1. Yep T, Patel VD, Slejko JF, Devine EB. Comparing Total and Disease Related Healthcare Cost for Glaucoma Patients by Disease Severity: A
Retrospective Claims Database Analysis. (In Progress)
Senior Manager, Global Health Economics and Outcomes Research
Allergan plc, Irvine, CA
MANUSCRIPTS FROM FELLOWSHIP 1. Keyloun KR, Hansen R, Hepp Z, Gillard P, Thase M, Devine EB. Adherence and Persistence Across Antidepressant Therapeutic Class: A
Retrospective Claims Analysis Among Insured US Patients with Major Depressive Disorder (MDD). CNS Drugs. 2017 May;31(5):421-432.2. Mathias P, Hendrix N, Wang W, Keyloun KR, Khelifi M, Tarcyzy-Hornoch P, Devine EB. Characterizing pharmacogenomic-guided
medication use with a clinical data repository. Clin Pharmacol Ther. 2017 Aug;102(2):340-348.3. Chin L, Devine B, Baradaran S, Keyloun K, Canestaro W, Pham J. Characterizing the Strength of Evidence in FDA Labels for
Pharmacogenomic Biomarker-Guided Medication Use. AMIA Joint Summits on Translational Science. 2017 Jul; eCollection.
PAST FELLOWS
KATELYN KEYLOUN
PharmD, MS2014-2016
VANESSA SHIH
PharmD, MS2014-2016
TRACY YEPPharmD, MS
2013-2015
Associate Health Economist, Evidence for Access (BioOncology) - US Medical AffairsGenentech, Inc., San Francisco, CA
MANUSCRIPTS FROM FELLOWSHIP1. Shapouri S, Devine EB, Keyloun KR, Gillard PJ, Sabbatini AK, Bansal A. Predicting Hospitalizations and Returns to the Emergency
Department 30-Days Post Emergency Department Discharge Among Patients with Acute Bacterial Skin and Skin Structure Infections. (In Progress)
SHEILA SHAPOURIPharmD, MS
2016-2018
Manager, Medical Affairs (HEOR)Neurocrine Biosciences, San Diego, CA
MANUSCRIPTS FROM FELLOWSHIP1. Serbin M, Devine B, Campbell J, Basu A. Assessing the Societal Burden of Glaucoma Patients With vs. Without Physical or Mental
Comorbidities. (In Progress)
MICHAEL SERBIN
PharmD, MS2016-2018
9
Senior Manager, Global Health Economics and Outcomes Research
Allergan plc, Irvine, CA
MANUSCRIPTS FROM FELLOWSHIP 1. Tung A, Hepp Z, Bansal A, Devine EB. Characterizing Health Care Utilization, Direct Costs, and Comorbidities Associated with Interstitial
Cystitis: A Retrospective Claims Analysis. Journal of managed care & specialty pharmacy. 2017; 23(4):474-482. 2. Dmochowski R, Brucker B, Cole E, Kawahara S, Pulicharam R, Burk C, Tung A, Hale D. Economic Burden of Illness in Adult Patients with
Nocturia. (In Progress)
AMY TUNG
PharmD, MS2015-2017
Senior Manager, Global Health Economics and Outcomes Research
Allergan plc, Irvine, CA
MANUSCRIPTS FROM FELLOWSHIP 1. Baradaran S, Black D, Keyloun K, Hansen R, Gillard P, Devine B; The Impact of Acute Kidney Injury on the Risk of Mortality and Health Care
Utilization Among Patients Treated With Polymyxins for Severe Gram-Negative Infections, Open Forum Infectious Diseases, Volume 5, Issue 8, 1 August 2018.
2. Kagan R, Martin A, Sarri G, Guo Y, Baradaran S, Harrington A. The Burden of Illness Associated with Symptomatic Vulvovaginal Atrophy (VVA): A Systematic Review. (In Progress)
3 Chin L, Devine B, Baradaran S, Keyloun K, Canestaro W, Pham J. Characterizing the Strength of Evidence in FDA Labels for Pharmacogenomic Biomarker-Guided Medication Use. AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science. 2017; 2017:30-39.
SARAH BARADARAN
PharmD, MS2015-2017
AGN7980_Allergan UW Fellowship Brochure_2018-mech.indd 10 10/15/18 10:27 AM
GHEOR Fellowship Program 2019-2021
Health Economist
Genentech, San Francisco, CA
MANUSCRIPTS FROM FELLOWSHIP1. Stewart Williams JA, Wallick CJ, Byles JE, Doran CM.Assessing patterns of use of cardio-protective polypill component medicines in
Australian women. Drugs Aging (2013)30:193-2032. Wallick CJ, Hansen RN, Campbell J, Kiss S, Kowalski JW, Sullivan SD. Comorbidity and Health Care Resource Use Among Commercially
Insured Non-Elderly Patients With Diabetic Macular Edema. Ophthalmic surgery, lasers & imaging retina. 2015 Jul-Aug;46(7):744-513. Wallick CJ, Sullivan SD, Hansen RN, Campbell JH, Kowalski JW. The Cost of Diabetic Macular Edema in a Commercially Insured Working
Age Population Opthalmic Surg Lasers Imaging Retina. 2015 Jul-Aug;46(7):744-51
CHRIS WALLICK
PharmD, MS2012-2014
Associate Director, Patient Reported Outcomes The Janssen Pharmaceutical Companies of Johnson & Johnson, Raritan, NJ
MANUSCRIPTS FROM FELLOWSHIP1. Campbell JD, Gries KS, Watanabe JH, Ravelo A, Dmochowski RR, Sullivan SD. Treatment Success for Overactive Bladder with Urinary
Urge Incontinence Refractory to Oral Antimuscarinics: A Review of Published Evidence. BMC Urology, 2009; 9(18)
Associate Professor, UCSD Skaggs School of PharmacySan Diego, CA
MANUSCRIPTS FROM FELLOWSHIP1. Campbell JD, Gries KS, Watanabe JH, Ravelo A, Dmochowski RR, Sullivan SD. Treatment Success for Overactive Bladder with Urinary Urge
Incontinence Refractory Oral Antimuscarinics. BMC Urology, 2009 Nov;20;9(18).2. Watanabe JH, Campbell JD, Ravelo A, Chancellor MB, Kowalski J, Sullivan SD. Cost Analysis of Interventions for Antimuscarinic Refractory
Patients with Overactive Bladder. Urology, 2010 Oct;76(4):835-40.3. Sand P, Rovner E, Dmochoswki R, Watanabe JH, Oefelein MG. Once-daily Trospium Chloride 60 mg Extended Release is Safe and Effective in
Subjects with the Overactive Bladder Syndrome who Use Multiple Concomitant Medications. Drugs Aging, 2011 Feb;1;28(2):151-604. Patel VD, Watanabe JH, Strauss JA, Dubey AT. Work productivity loss in patients with dry eye disease: an online survey. Curr Med Res
Opin, 2011 May, 27(5):1041-8.
Executive Director, Global Health Economics and Outcomes Research
Allergan plc, Irvine, CA
MANUSCRIPTS FROM FELLOWSHIP1. Gillard PJ, Devine B, Varon SF, Liu L, Sullivan SD. Mapping from Disease- Specific Measures to Health-State Utility Values in Individuals
with Migraine. Value in Health 2012;15(3):485-94.2. Doan QV, Brashear A, Gillard PJ, Varon SF, Turkel CC, Vandenburgh AM, Elovic EP. Relationship Between Disability Due to Upper-Limb
Post-Stroke Spasticity and Health-Related Quality of Life and Caregiver Burden, PM&R 2012;4(1):4-10.
Associate Director, Health Economics and Outcomes Research
Kite Pharma, Santa Monica, CA
MANUSCRIPTS FROM FELLOWSHIP1. Lin VW, Ringold S, Devine BE. Comparison of Ustekinumab with other Biologic Agents for Treatment of Moderate-to-Severe Psoriasis:
A Bayesian Network Meta-Analysis. Arch Dermatol. 2012 Dec;148(12):1403-102. Lin VW, Wright A, Flum DR, Alfonso RA, Garrison LP, Sullivan SD. Patients’ experience and outcomes after laparoscopic adjustable gastric
banding in Washington State. Surg Obes Relat Dis. 2013 Sep-Oct;9(5):701-53. Lin VW, Wong ES, Wright A. Association between health-related quality of life and body mass after adjustable gastric banding: a
nonlinear approach. Value in Health. 2013 Jul;16(5):823-9
Consultant, Health Economics and Outcomes Research
Seattle, WA
MANUSCRIPTS FROM FELLOWSHIP1. JC Sanderson, EB Devine, RB Lipton, LM Bloudek, SF Varon, AM Blumenfeld, PJ Goadsby, DC Buse, SD Sullivan. Headache-related health
resource utilization in chronic and episodic migraine across six countries. J Neurol Neurosurg Psychiatry. 2013 Dec;84(12):1309-172. Messali A, Sanderson JC, Blumenfeld AM. Direct and Indirect Costs of Chronic and Episodic Migraine in the United States: A Web-Based
Survey. Headache. 2016 Feb;56(2):306-22
JONATHAN H. WATANABE
PharmD, MS, PhD2007-2009
Associate Director, Health Economics and Outcomes Research
Seattle Genetics, Seattle, WA
MANUSCRIPTS FROM FELLOWSHIP1. Hepp Z, David DW, Gillard P, Varon SF, Hansen RN, Devine EB. Adherence to oral migraine-preventive medications among patients with
chronic migraine. Cephalalgia. 2015 May;35(6):478-88.2. Forrester S, Hepp Z, Roth J, Wirtz H, Devine EB. Cost-effectiveness of a computerized provider order entry system in improving
medication safety in ambulatory care. Value Health. 2014 Jun;17(4):340-9
ZSOLT HEPPPharmD, MS
2012-2014
JOANNA SANDERSON
PharmD, MS2011-2013
VINCENT W. LIN
PharmD, MS2010-2012
PATRICK GILLARD
PharmD, MS2009-2010
KATHARINE S. GRIES
PharmD, MS, PHD2008-2010
10
AGN7980_Allergan UW Fellowship Brochure_2018-mech.indd 11 10/15/18 10:27 AM
NYSE:AGN | www.Allergan.com
© 2018 Allergan. ® Marks owned by Allergan. All rights reserved
APPLICATION INFORMATIONInterested students must apply to both the University of Washington Graduate
School, as well as the The Comparative Health Outcomes, Policy, and Economics
(CHOICE) Institute. The online application process can be found at:
https://sop.washington.edu/choice/graduate-education-training-programs/
fellowships/
CONTACT INFORMATIONIf you have any questions, please contact:
UNIVERSITY OF WASHINGTON
Shannon Dwyer
Program Operations Specialist
1959 NE Pacific St
Box 357630
Seattle, WA 98195-7630
E-Mail: [email protected]
Phone: (206) 616-1383
Fax: (206) 543-3835
DEADLINE The application deadline is
December 7, 2018
and the start date of the
Fellowship is July 1, 2019
ALLERGAN PLC
Patrick Gillard, PharmD, MS
Executive Director, GHEOR
2525 Dupont Drive
Irvine, CA 92612
E-Mail: [email protected]
Phone: (714) 246-2354
Applicants for this fellowship must have a degree in pharmacy and have some
research experience (preference will be given to those with a high academic
standing). Excellent written and verbal communication skills are also essential.
Applicants will be required to submit their curriculum vitae, a letter
describing their career goals, and three letters of recommendation.
Selection of fellows will be made by a steering committee
composed of the University of Washington faculty
members and representatives from Allergan.
APPLICATION ELIGIBILITY
UniversityUNIVERSITY OF WASHINGTONThe Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute
Programs Offered
University Location
Allergan Location
Program Length
Eligibility
Seattle, WA
Irvine, CA
2 years
Degree in Pharmacy
Global Health Economics and Outcomes Research
A L L E R G A N F E L LO W S H I P P R O G R A M S
AGN7980_Allergan UW Fellowship Brochure_2018-mech.indd 12 10/15/18 10:27 AM